2025年2月27日 · Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.

At Grifols, we are pioneers in the development of therapies derived from blood and plasma. We contribute to building the future of healthcare to improve people's well-being. Since 1909, we have been defined by passion, innovation, teamwork and a sense of responsibility.

Grifols es una compañía global líder en el sector de la salud. Nuestros innovadores medicamentos derivados del plasma, otros productos biofarmacéuticos y soluciones en medicina transfusional permiten mejorar la calidad de vida de millones de pacientes en todo el mundo.

Grifols USA was established in 2003. Based in Los Angeles, we cover the U.S. market where we offer a comprehensive portfolio of Grifols products and services. The company is one of the largest producers of life-saving plasma medicines and other innovative biopharmaceutical solutions in the world.

By observing, analyzing, asking questions and experimenting, scientists make discoveries that lead to the progress that benefits people. Grifols has established a series of prizes, all of which aim to incentivize scientific investigation across different areas of research.

Accelerate pre-transfusion testing with Grifols' comprehensive typing, screening & identification assays.

Grifols Deutschland wurde 1997 gegründet. Von Frankfurt aus leiten wir den Biopharma-Vertrieb in Deutschland und den Diagnostic-Vertrieb in den Märkten Deutschland, Österreich und Schweiz (DACH). Wir bieten ein umfassendes Portfolio an Grifols-Produkten und -Services.

Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029. February 27, 2025

Barcelona, Spain, March 13, 2025 – Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced positive results from its phase 2/3 clinical trial (NCT02176863) evaluating the efficacy and safety of Grifols intravenous immunoglobulin (IVIG) to treat patients with ...